Short Interest Watching: Teva Pharmaceutical Industries L (NYSE:TEVA) Sellers Increased By 9.94% Their Shorts

November 17, 2016 - By Ruchi Gupta   ·   0 Comments

Short Interest Watching: Teva Pharmaceutical Industries L (NYSE:TEVA) Sellers Increased By 9.94% Their Shorts

The stock of Teva Pharmaceutical Industries L (NYSE:TEVA) registered an increase of 9.94% in short interest. TEVA’s total short interest was 10.81 million shares in November as published by FINRA. Its up 9.94% from 9.83M shares, reported previously. With 5.40M shares average volume, it will take short sellers 2 days to cover their TEVA’s short positions. The short interest to Teva Pharmaceutical Industries L’s float is 1.34%. About 3.44 million shares traded hands. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 31.01% since April 15, 2016 and is downtrending. It has underperformed by 35.63% the S&P500.

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The company has a market cap of $37.84 billion. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. It has a 26.24 P/E ratio. The Firm operates through two divisions: Generic medicines and Specialty medicines.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Ratings Coverage

Out of 22 analysts covering Teva Pharma (NYSE:TEVA), 13 rate it a “Buy”, 0 “Sell”, while 9 “Hold”. This means 59% are positive. Teva Pharma has been the topic of 40 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Goldman Sachs upgraded the stock to “Buy” rating in Monday, November 23 report. The rating was maintained by Mizuho on Wednesday, November 16 with “Neutral”. The firm earned “Outperform” rating on Friday, February 19 by Wells Fargo. The firm earned “Neutral” rating on Tuesday, September 29 by Nomura. The firm has “Neutral” rating by Credit Suisse given on Wednesday, May 4. Maxim Group maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) rating on Monday, July 27. Maxim Group has “Buy” rating and $74 price target. Argus Research maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Tuesday, July 28 with “Buy” rating. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Outperform” rating by Oppenheimer on Friday, September 2. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned “Buy” rating by Jefferies on Friday, October 30. The firm has “Overweight” rating by Morgan Stanley given on Tuesday, May 3.

TEVA Company Profile

Teva Pharmaceutical Industries Limited, incorporated on February 13, 1944, is a global pharmaceutical company. The Firm is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Firm operates through two divisions: Generic medicines and Specialty medicines. The Firm has a global portfolio of approximately 1,000 molecules.

Another recent and important Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) news was published by Investorplace.com which published an article titled: “Why Nokia Corp (ADR) (NOK), Teva Pharmaceutical Industries Ltd (ADR) (TEVA …” on November 15, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ruchi Gupta


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>